Valuation
- Market cap
- 875,731,000
- Revenue TTM
- $0
- Net income TTM
- $-127,410,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 1,109,800
- Avg volume
- 890,126
- Day's range
- $13.31 – $14.17
- Shares out
- 63,597,000
- Stochastic %K
- 21%
- Beta
- 1.64
- Analysts
- Strong Sell
- Price target
- $49.89
Company profile
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc....
Show more
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 781 312 3013
- Website
- https://jadebiosciences.com
- Address
- Building 23, Suite 105 221 Crescent Street, Waltham, United States
Latest news
No headlines yet.
